by Ivo De Nooijer | Jul 14, 2025 | Blog
Repurposing existing drugs for new indications has emerged as a powerful strategy in modern drug development. Yet, the business models that underpin successful repurposing ventures remain diverse and highly dependent on how intellectual property (IP) is managed. In...
by Ivo De Nooijer | Mar 20, 2025 | Blog
We at Orfenix are committed to socially responsible pharmaceutical practices. These practices emphasize balancing innovation with accessibility, long-term pharmaceutical sustainability, and equity. These principles drive efforts to create strategic public-private...
by Ivo De Nooijer | Nov 12, 2024 | Blog
Drug development is a long, expensive, and risky process. It takes an average of 10-15 years and requires a multi billion investment to bring a new drug from the laboratory to patients. Despite these costs, only about 10% of drugs that begin clinical trials ever...
by Ivo De Nooijer | Oct 17, 2024 | Blog
Orfenix welcomes a recently published report of the Medicines Patent Pool, in partnership with Boston Consulting Group, shows how voluntary licensing brings both improved access to medicines, in particular in low and middle-income countries and economic benefits to...
by Ivo De Nooijer | Oct 17, 2024 | Blog
Orfenix is proud to announce that Ivo de Nooijer has formally joined Orfenix as a shareholder and partner as of 1 July 2024. Vincent van de Wel, the founder, said, “Ivo joining this team is the next step in the development of Orfenix; Ivo brings extensive expertise in...
